This study revealed the role of the EZH2/miR-139-5p/TOP2A axis in promoting HCC progression via the regulation of cellular senescence and suggested that targeting EZH2 to induce senescence and then destroy senescent cells is a promising therapeutic strategy for HCC. This evidence concerns the gene EZH2 and hepatocellular carcinoma.